Evidence map›Paper›PMID 35018339›Full record

ArticleGlobal epidemiology2022

Evolving mortality and clinical outcomes of hospitalized subjects during successive COVID-19 waves in Catalonia, Spain.

Albert Roso-Llorach, Xavier Serra-Picamal, Francesc X Cos, Meritxell Pallejà-Millán, Lourdes Mateu, Antoni Rosell, Benito Almirante, Jaume Ferrer, Mercè Gasa, Carlota Gudiol and 11 more

Open access · goldAbstract read
In one paragraph

Article in Global epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Use of chronic medications and risk of death due to COVID-19 in hospitalised patients.European journal of hospital pharmacy : science and practice · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Comparison of the clinical characteristics and outcomes of Japanese patients with COVID-19 treated in primary, secondary, and tertiary care facilities.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2023
    Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 14 institutions in 2 countries.

Albert Roso-LlorachFundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gorina (IDIAPJGol), Barcelona, Catalonia, Spain.
Xavier Serra-PicamalInstitut Català de la Salut (ICS), Barcelona, Catalonia, Spain.
Francesc X CosInstitut Català de la Salut (ICS), Barcelona, Catalonia, Spain.
Meritxell Pallejà-MillánUnitat de Suport a la Recerca Tarragona-Reus, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Reus, Catalonia, Spain.
Lourdes MateuUniversitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Catalonia, Spain.
Antoni RosellUniversitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Catalonia, Spain.
Benito AlmiranteUniversitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Catalonia, Spain.
Jaume FerrerUniversitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Catalonia, Spain.
Mercè GasaDepartment of Respiratory Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain.
Carlota GudiolInstitut d'investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Catalonia, Spain.
Anna Maria MorenoHospital Universitari Arnau de Vilanova, IRBL, Lleida, Catalonia, Spain.
Jose Luís Morales-RullHospital Universitari Arnau de Vilanova, IRBL, Lleida, Catalonia, Spain.
Maria RexachDepartment of Internal Medicine, Hospital Universitari Doctor Josep Trueta, Girona, Catalonia, Spain.
Gladis SabaterDepartment of Internal Medicine, Hospital Universitari Doctor Josep Trueta, Girona, Catalonia, Spain.
Teresa AuguetHospital Universitari de Tarragona Joan XXIII, Tarragona, Catalonia, Spain.
Francesc VidalHospital Universitari de Tarragona Joan XXIII, Tarragona, Catalonia, Spain.
Ana LeridaHospital de Viladecans, Viladecans, Catalonia, Spain.
Josep RebullHospital Universitari Verge de la Cinta, Tortosa, Catalonia, Spain.
Kamlesh KhuntiDiabetes Research Center, University of Leicester, Leicester General Hospital, Leicester, UK.
Josep M ArgimonInstitut Català de la Salut (ICS), Barcelona, Catalonia, Spain.
Roger ParedesUniversitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Catalonia, Spain.
Institut Català de la Salut · ESHospital Universitari Arnau de Vilanova · ESHospital Universitari de Girona Doctor Josep Trueta · ESHospital Universitari Germans Trias i Pujol · ESInstitut Universitari d'Investigació en Atenció Primària Jordi Gol · ESUniversitat Autònoma de Barcelona · ESBellvitge University Hospital · ESHospital de Tortosa Virgen de la Cinta · ESHospital de Viladecans · ESInstitut d'Investigació Biomédica de Bellvitge · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESInstitut d'Investigació Sanitària Pere Virgili · ESLeicester General Hospital · GBUniversidad Rovira i Virgili · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe changes in shield strategies, treatments, emergence variants, and healthcare pathways might shift the profile and outcome of patients hospitalized with COVID-19 in successive waves of the outbreak.

methodsWe retrospectively analysed the characteristics and in-hospital outcomes of all patients admitted with COVID-19 in eight university hospitals of Catalonia (North-East Spain) between Feb 28, 2020 and Feb 28, 2021. Using a 7-joinpoint regression analysis, we split admissions into four waves. The main hospital outcomes included 30-day mortality and admission to intensive care unit (ICU).

findingsThe analysis included 17,027 subjects admitted during the first wave (6800; 39.9%), summer wave (1807; 10.6%), second wave (3804; 22.3%), and third wave (4616; 27.1%). The highest 30-day mortality rate was reported during the first wave (17%) and decreased afterwards, remaining stable at 13% in the second and third waves (overall 30% reduction); the lowest mortality was reported during the summer wave (8%, 50% reduction). ICU admission became progressively more frequent during successive waves. In Cox regression analysis, the main factors contributing to differences in 30-day mortality were the epidemic wave, followed by gender, age, diabetes, chronic kidney disease, and neoplasms.

interpretationAlthough in-hospital COVID-19 mortality remains high, it decreased substantially after the first wave and is highly dependent of patient's characteristics and ICU availability. Highest mortality reductions occurred during a wave characterized by younger individuals, an increasingly frequent scenario as vaccination campaigns progress.

fundingThis work did not receive specific funding.

Indexed as

Clinical characteristicsCoronavirus disease 2019 (Covid-19)Hospital mortalityRisk factorsSocioeconomic characteristics

Identifiers

PMID35018339
PMCPMC8739818
OpenAlexW4225278544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.